TRIPLE DOWN ALERT - Plus 6 Hot Stocks
Published 23-MAR-2021 10:35 A.M.
6 minute read
EuroManganese (ASX:EMN) just announced an oversubscribed $30M cap raise from ESG funds and strategic investors.
We have “tripled down” on EMN and invested in the placement at 60c (we participated in both the previous EMN placements too).
We reckon EMN is in the prime position to supply High Purity Manganese to the European Union, who are trying to be the fastest continent to fully transition to electric vehicles.
The $30M in funds raised will accelerate development of EMN’s project, allowing for completion of all site and technical work required for a final investment decision next year.
Speaking of our favourite European battery metals stocks, VUL is another one making huge progress in Europe, in Zero Carbon Lithium:
Vulcan Energy (ASX:VUL) was our 2020 “Top Pick of the Year” and now has the backing of Australia’s richest person - mining magnate Gina Rinehart, and ESG investors after raising $120M at $6.50/share. We also participated in this placement.
This funding round has set VUL up for the next couple of years.
VUL has been hitting investors with almost one announcement per week and looks like the share price is consolidating nicely around the $6.50 placement price, hopefully in anticipation of its next leg up.
Today VUL announced a world first lithium CO2 traceability agreement, and last week they announced former Tesla Head of Battery and Energy Supply Chain, Annie Liu to its Board.
Ms Liu managed Tesla’s multi-billion dollar strategic partnerships and sourcing portfolios - including raw materials sourcing efforts such as lithium for battery cells...
New board appointment Ms Liu could be paramount in VUL’s goal to become the world’s first Zero Carbon Lithium producer - we suspect she has a very impressive contact book in the EV space.
Speaking of key female board appointments in Zero Carbon green investments - PRL (Zero Carbon Hydrogen) just announced that experienced exec Kylah Morrison has joined their Board:
Just like VUL, Province Resources (ASX:PRL) has added a highly experienced female executive to the Board - adding a superstar to their ranks and increasing their credentials as a modern ESG company.
Ms Morrison brings extensive experience in local community engagement and indigenous organisations.
Kylah Morrison could have a massive influence on how quickly PRL can bring its Zero Carbon Hydrogen project to market.
PRL’s share price has been on a huge run since we nominated it for our 2021 Small Cap Pick of the Year and then wrote about hydrogen aspirant Andrew Forrest's FMG lobbing in land applications around PRL’s land...
PRL has run from 6c to 18c in those few weeks...
Speaking of strong runners in our portfolio - PUR’s share price is off to the races in anticipation of drilling...
Pursuit Minerals (ASX:PUR) has a number of compelling EM targets in the Julimar province it is aiming to drill.
The Julimar province is home to the $1.6BN Chalice Mining discovery.
Our investment plan in December last year was anticipating that PUR would run in the lead up to their drilling event , which thankfully worked after PUR announced some pretty juicy EM targets.
We continue to be impressed in the strong run PUR is having.
Speaking of more strong share price runs in the lead up to drilling - 88E has been having a massive run of interest from its US listing on the OTC markets.
88 Energy (ASX:88E) continues to get significant interest in their “just days away” oil drilling results in Alaska.
88E was up over 40% in the overnight trading session in the USA with overseas chat rooms taking a shine to the stock.
Now thanks to the USA OTC listing and US chat room action we wrote about yesterday, 88E seems to be running.
We think the overnight momentum in the US on the OTC market is going to continue into today’s trading on the 88E, which shows the benefit of having a dual USA listing on the OTC.
Speaking of companies with OTC listings - CPH has confirmed its own OTC listing in the USA is only a few weeks away.
Creso Pharma (ASX: CPH) is a medical cannabis stock set to acquire 100% of a Canadian psychedelics company that has a steady supply of legal synthetic psilocybin to progress R&D initiatives.
We have been interested in the psychedelics space for a while now as we think it is a mega trend for mental health treatment over the next 10 years.
CPH, currently capped at ~ $200M, wants to see if its valuation can catch up to its billion dollar plus North American peers like MindMed and Compass Pathways.
We have been noticing a trend of ASX listed stocks going to list on the OTC (Over the Counter) exchange in the US, and performing extremely well.
The USA investor market is huge, and stocks can get some massive momentum, especially if the chatrooms like Reddit can take hold of them.
With a compelling story and now an imminent OTC listing, we hope there is more upside in CPH.
CPH is the only non-portfolio stock we write about as we originally took a position as a medium term trade.
However in recent months it has been knocking on the door for inclusion in our long term portfolio...
Speaking of our long term portfolio - we have invested in just 19 companies since 2018 and these are all intended as long term positions:
The stocks we wrote about today have been having a great run - you can see the rest of our portfolio stocks in the link below.
While some of our portfolio family have been quiet recently that doesn’t mean they haven’t been busy in the background.
We will aim to provide an update on all of the portfolio stocks in the coming weeks... Including some of the stragglers that have been a bit slow to move (looking at you GTR, AJX, TMR... ) and why we are still fully invested in them.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.